Shengyao Guangyan Pharmaceutical

Explore the latest insights on Shengyao Guangyan Pharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Shengyao Guangyan Pharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. ("Shengyao Guangyan"), a wholly‑owned subsidiary of Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE: 002370), signed a Letter of Intent (LOI) for Innovative Drug Technology Transaction…

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn's Disease – 35.8% Achieved Endoscopic Remission

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn’s Disease – 35.8% Achieved Endoscopic Remission

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now